Website: almaden.io   |   LinkedIn: linkedin.com/company/almaden-genomics

Bioinformatics Without the Bottleneck

How Almaden Genomics took a platform born at IBM Research and made genomic analysis accessible to every scientist

At a glance

  • Company: Almaden Genomics (almaden.io)
  • Headquarters: Dallas, Texas
  • Origins: Developed at IBM Research’s Almaden Lab in San Jose, California; launched as a standalone company in 2022
  • Offerings:nome® cloud-native omics analysis platform, plus Data Management and Informatics Services
  • Working with PSG on: Fractional commercialization services

Born at IBM Research

Almaden Genomics takes its name from IBM Research’s Almaden Lab in Silicon Valley, where its technology was first built and validated. In 2022, venture development firm Catalyze Dallas launched Almaden as a standalone company and brought along most of the bioinformaticians and engineers who created the platform.

The bottleneck in genomics

Sequencing is fast and affordable. Analysis isn’t. Biologists wait in line for bioinformaticians, pipelines are hard to build and reproduce, and data piles up faster than teams can interpret it.

g.nome®: genomic analysis for scientists and bioinformaticians

g.nome is a cloud-native platform that unites biologists and bioinformaticians in one environment:

  • Visual workflow building that turns complex code into easy-to-understand pipelines
  • Ready-to-use workflows and a curated toolkit library, including pre-built single-cell RNA-seq analysis
  • Custom pipelines for bioinformaticians who want full control
  • Cloud scale on AWS, with no infrastructure to manage
  • nome 2.0 adds enhanced analytics and interpretation tools

More than software

In 2025, Almaden launched a Data Management and Informatics Services business to help teams design data workflows, manage complex datasets, and implement advanced analytics. Partnerships with companies like Elucidata extend what researchers can do with their data.